lenalidomide has been researched along with sirolimus in 14 studies
| Studies (lenalidomide) | Trials (lenalidomide) | Recent Studies (post-2010) (lenalidomide) | Studies (sirolimus) | Trials (sirolimus) | Recent Studies (post-2010) (sirolimus) |
|---|---|---|---|---|---|
| 3,532 | 725 | 2,850 | 20,711 | 2,368 | 11,516 |
| Protein | Taxonomy | lenalidomide (IC50) | sirolimus (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 10 | |
| ATP-dependent translocase ABCB1 | Homo sapiens (human) | 1.25 | |
| Cytochrome P450 3A4 | Homo sapiens (human) | 2 | |
| Cytochrome P450 2C9 | Homo sapiens (human) | 2 | |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Mus musculus (house mouse) | 0.001 | |
| Cytochrome P450 2C19 | Homo sapiens (human) | 4 | |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | 0.0897 | |
| Peptidyl-prolyl cis-trans isomerase FKBP1A | Homo sapiens (human) | 0.0042 | |
| Regulatory-associated protein of mTOR | Homo sapiens (human) | 0.225 | |
| Target of rapamycin complex subunit LST8 | Homo sapiens (human) | 0.225 | |
| Broad substrate specificity ATP-binding cassette transporter ABCG2 | Homo sapiens (human) | 1.9 | |
| Solute carrier organic anion transporter family member 1B1 | Homo sapiens (human) | 1.1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.14) | 29.6817 |
| 2010's | 12 (85.71) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Anderson, KC; Antin, JH; Chauhan, D; Hideshima, T; Ishitsuka, K; Kumar, S; Le Gouill, S; Mitsiades, C; Munshi, NC; Podar, K; Raje, N; Richardson, P; Stirling, DI | 1 |
| Hagemeister, FB | 1 |
| Benson, DM; Byrd, JC; Chan, KK; Chen, CS; Chen, P; Farag, SS; Garr, CL; Grever, MR; Hade, EM; Hicks, WJ; Hofmeister, CC; Ji, J; Johnson, AJ; Kraut, EH; Lee, S; Liu, Z; Phelps, MA; Pichiorri, F; Rozewski, DM; Schaaf, LJ; Yang, X | 1 |
| Ramchandren, R | 1 |
| Moskowitz, AJ | 1 |
| Ogura, M | 1 |
| Falchook, G; Ganesan, P; Janku, F; Kies, M; Laday, S; Naing, A; Piha-Paul, S; Tsimberidou, AM; Wheler, J; Zinner, R | 1 |
| Anderson, KC; Burke, JN; Cirstea, DD; Ghobrial, IM; Hari, P; Hideshima, T; Laubach, JP; Mahindra, AK; Marcheselli, R; Munshi, NC; Raje, NS; Richardson, PG; Rodig, SJ; Schlossman, RL; Scullen, TA; Weller, EA; Yee, AJ | 1 |
| Choquet, S; Leblond, V; Nguyen, S; Souchet-Cömpain, L | 1 |
| Biernacka, M; Borycka, IS; Bujko, M; Błachnio, K; Grygorowicz, MA; Markowicz, S; Nowak, E; Paszkiewicz-Kozik, E; Rymkiewicz, G; Walewski, J | 1 |
| Abhyankar, S; Kabadi, SM; Signorovitch, J; Song, J; Telford, C; Yao, Z; Zhao, J | 1 |
| Besien, KV; Cohen, K; Fishkin, PAS; Karrison, TG; Kimball, AS; Kline, J; Major, A; Nattam, S; Petrich, AM; Rao, K; Rapoport, AP; Sleckman, BG; Smith, SM | 1 |
6 review(s) available for lenalidomide and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Maintenance and consolidation strategies in non-Hodgkin's lymphoma: A review of the data.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Combined Modality Therapy; Disease Progression; Disease-Free Survival; Everolimus; Hematopoietic Stem Cell Transplantation; Humans; Indoles; Lenalidomide; Lymphoma, Non-Hodgkin; Protein-Tyrosine Kinases; Radioimmunotherapy; Randomized Controlled Trials as Topic; Risk Factors; Rituximab; Secondary Prevention; Signal Transduction; Sirolimus; Survival Rate; Thalidomide; Treatment Outcome | 2010 |
Advances in the treatment of relapsed or refractory Hodgkin's lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Boronic Acids; Bortezomib; Brentuximab Vedotin; Drug Therapy; Everolimus; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Immunoconjugates; Immunotherapy; Lenalidomide; Protease Inhibitors; Pyrazines; Recurrence; Rituximab; Secondary Prevention; Sirolimus; Thalidomide | 2012 |
Novel agents in Hodgkin lymphoma.
Topics: Antineoplastic Agents; Bendamustine Hydrochloride; Brentuximab Vedotin; Everolimus; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Immunoconjugates; Lenalidomide; Nitrogen Mustard Compounds; Protein Kinase Inhibitors; Sirolimus; Thalidomide | 2012 |
Current and future therapeutic approach for Waldenström's macroglobulinemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Comorbidity; Disease Progression; Everolimus; Forecasting; Guillain-Barre Syndrome; Hematopoietic Stem Cell Transplantation; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Immunotherapy; Incidence; Lenalidomide; Myelin-Associated Glycoprotein; Protein Kinase Inhibitors; Pyrazines; Rituximab; Salvage Therapy; Sirolimus; Thalidomide; Transplantation, Autologous; Treatment Outcome; Waldenstrom Macroglobulinemia; Watchful Waiting | 2014 |
Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
Topics: Adenine; Antineoplastic Agents; Benzamides; Bortezomib; Humans; Lenalidomide; Lymphoma, Mantle-Cell; Neoplasm Recurrence, Local; Piperidines; Pyrazines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Treatment Outcome | 2019 |
5 trial(s) available for lenalidomide and sirolimus
| Article | Year |
|---|---|
Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Drug Interactions; Humans; Lenalidomide; Maximum Tolerated Dose; Multiple Myeloma; Neoplasm Recurrence, Local; Sirolimus; Survival Rate; Thalidomide; Tissue Distribution; Treatment Outcome | 2011 |
[Current development of new drugs in malignant lymphoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bendamustine Hydrochloride; Boronic Acids; Bortezomib; Brentuximab Vedotin; Diphtheria Toxin; Drug Discovery; Everolimus; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Inotuzumab Ozogamicin; Interleukin-2; Lenalidomide; Lymphoma; Lymphoma, B-Cell; Nitrogen Mustard Compounds; Purine Nucleosides; Pyrazines; Pyrimidinones; Recombinant Fusion Proteins; Sirolimus; Thalidomide; Vorinostat | 2012 |
Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Female; Humans; Lenalidomide; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Sirolimus; Thalidomide; TOR Serine-Threonine Kinases; Young Adult | 2013 |
Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Everolimus; Female; Gene Expression Profiling; Humans; Immunohistochemistry; Lenalidomide; Male; Middle Aged; Multiple Myeloma; Recurrence; Sirolimus; Thalidomide; Treatment Outcome | 2014 |
Phase I/II clinical trial of temsirolimus and lenalidomide in patients with relapsed and refractory lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Lenalidomide; Neoplasm Recurrence, Local; Phosphatidylinositol 3-Kinases; Sirolimus; TOR Serine-Threonine Kinases; Transplantation, Autologous; Treatment Outcome | 2022 |
3 other study(ies) available for lenalidomide and sirolimus
| Article | Year |
|---|---|
Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.
Topics: Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Division; Cell Line, Tumor; Drug Synergism; Humans; Lenalidomide; Multiple Myeloma; Protein Kinases; Sirolimus; Stromal Cells; Thalidomide; TOR Serine-Threonine Kinases | 2004 |
Lenalidomide potentiates CD4
Topics: Adult; Aged; B-Lymphocytes; Blood Donors; CD4 Antigens; Cell Proliferation; Cells, Cultured; Female; Humans; Immunologic Factors; Interleukin-2 Receptor alpha Subunit; Lenalidomide; Lymphoma; Male; Middle Aged; Sirolimus; T-Lymphocytes, Regulatory; Thalidomide | 2017 |
Chemotherapy of mantle cell lymphoma relapsed or refractory chronic lymphocytic leukaemia.
Topics: Adenine; Antineoplastic Agents; Bendamustine Hydrochloride; Bortezomib; Chromosomes, Human, Pair 17; Cytarabine; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Mantle-Cell; Mutation; Neoplasm Recurrence, Local; Piperidines; Pyrazoles; Pyrimidines; Rituximab; Sirolimus; Thalidomide; Tumor Suppressor Protein p53; Vidarabine | 2016 |